Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Treatment of Relapsed Wilms Tumor

  • Chapter
  • First Online:
Renal Tumors of Childhood

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 938 Accesses

Abstract

The outlook for children with newly diagnosed Wilms tumors (WT) has improved dramatically with the advent of multimodal therapy, which includes surgery, chemotherapy, and for some, radiation therapy, with survival rates currently approaching 90 % (Lemerle et al. 1983; D’Angio et al. 1981, 1976). Although the overall relapse rate for children with WT has decreased to less than 15 %, the overall long-term survival for patients with recurrent disease remains at approximately 50 % (Grundy et al. 1989; Pinkerton et al. 1991; Pein et al. 1998; Kremens et al. 2002; Tannous et al. 2000). Due to the small numbers of relapsed patients, advancements in the treatment of these patients have remained a challenge. Investigators from different cooperative groups have evaluated the role of different therapeutic strategies in an attempt to improve the outcomes of patients with recurrent WT. Therapy for these patients depends on characteristics of their primary disease, extent of previous therapy, and time from initial diagnosis to relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abu-Ghosh AM, Krailo MD, Goldman SC et al (2002) Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol 13:460–469

    Article  CAS  PubMed  Google Scholar 

  • Adamson PC, Matthay KK, O’Brien M, Reaman GH, Sato JK, Balis FM (2007) A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: a Pediatric Oncology Branch, NCI and Children’s Oncology Group Study. Pediatr Blood Cancer 49:661–665

    Article  PubMed  Google Scholar 

  • Bardeesy N, Beckwith JB, Pelletier J (1995) Clonal expansion and attenuated apoptosis in Wilms’ tumors are associated with p53 gene mutations. Cancer Res 55:215–219

    CAS  PubMed  Google Scholar 

  • Benesch M, Windelberg M, Sauseng W et al (2008) Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 19:807–813

    Article  CAS  PubMed  Google Scholar 

  • Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25:4622–4627

    Article  CAS  PubMed  Google Scholar 

  • Campbell AD, Cohn SL, Reynolds M et al (2004) Treatment of relapsed Wilms’ tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children’s Memorial Hospital. J Clin Oncol 22:2885–2890

    Article  CAS  PubMed  Google Scholar 

  • Casey DA, Wexler LH, Merchant MS et al (2009) Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53:1029–1034

    Article  PubMed  Google Scholar 

  • D’Angio GJ, Evans AE, Breslow N et al (1976) The treatment of Wilms’ tumor: results of the national Wilms’ tumor study. Cancer 38:633–646

    Article  PubMed  Google Scholar 

  • D’Angio GJ, Evans A, Breslow N et al (1981) The treatment of Wilms’ tumor: results of the Second National Wilms’ Tumor Study. Cancer 47:2302–2311

    Article  PubMed  Google Scholar 

  • Dallorso S, Dini G, Faraci M, Spreafico F (2008) SCT for Wilms’ tumour. Bone Marrow Transplant 41(Suppl 2):S128–S130

    Article  PubMed  Google Scholar 

  • Daw NC, Anderson JR, Hoffer FA et al (2014) A phase 2 study of vincristine and irinotecan in mestastatic diffuse anaplastic Wilms tumor: results from Children’s Oncology Group Study AREN0321. J Clin Oncol 32 (5s) suppl abstr 10032.

    Google Scholar 

  • De Camargo B, Melarango R, Saba e Silva N et al (1994) Phase II study of carboplatin as a single drug for relapsed Wilms’ tumor: experience of the Brazilian Wilms’ Tumor Study Group. Med Pediatr Oncol 22:258–260

    Article  PubMed  Google Scholar 

  • Dome JS, Liu T, Krasin M et al (2002) Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children’s Research Hospital. J Pediatr Hematol Oncol 24:192–198

    Article  PubMed  Google Scholar 

  • Dome JS, Neale G, Hill DA et al (2005) Anti-tumor activity of topotecan against Wilms’ tumor: translation of a xenograft model to phase II study. Pediatr Blood Cancer 45:432–433

    Google Scholar 

  • Dome JS, Cotton CA, Perlman EJ et al (2006) Treatment of anaplastic histology Wilms’ tumor: results from the fifth National Wilms’ Tumor Study. J Clin Oncol 24:2352–2358

    Article  PubMed  Google Scholar 

  • Fuchs J, Szavay P, Luithle T, Furtwangler R, Graf N (2008) Surgical implications for liver metastases in nephroblastoma–data from the SIOP/GPOH study. Surg Oncol 17:33–40

    Article  PubMed  Google Scholar 

  • Garaventa A, Hartmann O, Bernard JL et al (1994) Autologous bone marrow transplantation for pediatric Wilms’ tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 22:11–14

    Article  CAS  PubMed  Google Scholar 

  • Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast TH (2003) Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 56:107–113

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Green DM, Breslow NE, Ii Y et al (1991) The role of surgical excision in the management of relapsed Wilms’ tumor patients with pulmonary metastases: a report from the National Wilms’ Tumor Study. J Pediatr Surg 26:728–733

    Article  CAS  PubMed  Google Scholar 

  • Green DM, Beckwith JB, Breslow NE et al (1994) Treatment of children with stages II to IV anaplastic Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 12:2126–2131

    CAS  PubMed  Google Scholar 

  • Green DM, Cotton CA, Malogolowkin M et al (2007) Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 48:493–499

    Article  PubMed  Google Scholar 

  • Gross RE, Neuhauser EB (1950) Treatment of mixed tumors of the kidney in childhood. Pediatrics 6:843–852

    CAS  PubMed  Google Scholar 

  • Grundy P, Breslow N, Green DM, Sharples K, Evans A, D’Angio GJ (1989) Prognostic factors for children with recurrent Wilms’ tumor: results from the Second and Third National Wilms’ Tumor Study. J Clin Oncol 7:638–647

    CAS  PubMed  Google Scholar 

  • Ha TC, Spreafico F, Graf N, Dallorso S, Dome JS, Malogolowkin M, Furtwängler R, Hale JP, Moroz V, Machin D, Pritchard-Jones K (2013) An international strategy to determine the role of high dose therapy in recurrent Wilms’ tumour. Eur J Cancer 49(1):194–210. doi:10.1016/j.ejca.2012.07.010

    Article  CAS  PubMed  Google Scholar 

  • Hale J, Hobson R, Moroz V, Satori P (2008) Results of UK Children’s Cancer and Leukemia Group (CCLG) protocol for relapsed Wilms tumor (UKWR): unified relapse strategy improves outcome. In: 40th meeting of International Society of Paediatric Oncology, p 62

    Google Scholar 

  • Italiano A, Sirvent N, Michiels JF, Peyrade F, Otto J, Thyss A (2005) Tumour response to paclitaxel in an adult with relapsed nephroblastoma. Lancet Oncol 6:252–253

    Article  PubMed  Google Scholar 

  • Kremens B, Gruhn B, Klingebiel T et al (2002) High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 30:893–898

    Article  CAS  PubMed  Google Scholar 

  • Kung FH, Desai SJ, Dickerman JD et al (1995) Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 17:265–269

    Article  CAS  PubMed  Google Scholar 

  • Kushner BH, Kramer K, Modak S et al (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24:5271–5276

    Article  CAS  PubMed  Google Scholar 

  • Lemerle J, Voute PA, Tournade MF et al (1983) Effectiveness of preoperative chemotherapy in Wilms’ tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1:604–609

    CAS  PubMed  Google Scholar 

  • Malogolowkin MH, Casak SJ, Feusner J et al (1994) Carboplatin and etoposide alternating with ifosfamide and doxorubicin for the treatment of children with recurrent Wilms’ tumors. Proc Am Soc Clin Oncol 13:424, (abstract no. 1453)

    Google Scholar 

  • Malogolowkin M, Cotton CA, Green DM et al (2008) Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 50:236–241

    Article  PubMed  Google Scholar 

  • Mascarenhas L, Lyden ER, Breitfel PP et al (2010) Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol 28:4658

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • McGregor LM, Spunt SL, Santana VM et al (2009) Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer 115:655–664

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Metzger ML, Stewart CF, Freeman BB 3rd et al (2007) Topotecan is active against Wilms’ tumor: results of a multi-institutional phase II study. J Clin Oncol 25:3130–3136

    Article  CAS  PubMed  Google Scholar 

  • Natrajan R, Little SE, Sodha N et al (2007) Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms’ tumour. J Pathol 211:52–59

    Article  CAS  PubMed  Google Scholar 

  • Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C (1998) Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315–318

    Article  CAS  PubMed  Google Scholar 

  • Pappo AS, Lyden E, Breitfeld P et al (2007) Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J Clin Oncol 25:362–9

    Article  CAS  PubMed  Google Scholar 

  • Pein F, Pinkerton R, Tournade MF et al (1993) Etoposide in relapsed or refractory Wilms’ tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children’s Cancer Study Group. J Clin Oncol 11:1478–1481

    CAS  PubMed  Google Scholar 

  • Pein F, Tournade MF, Zucker JM et al (1994) Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms’ tumor–a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 12:931–936

    CAS  PubMed  Google Scholar 

  • Pein F, Michon J, Valteau-Couanet D et al (1998) High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms’ tumor: a French Society of Pediatric Oncology study. J Clin Oncol 16:3295–3301

    CAS  PubMed  Google Scholar 

  • Pein F, Rey A, de Kraker J et al (1999) Multivariate analysis of adverse prognostic factors (APF) in children with recurrent (Rec) Wilms’ tumor (WT) after initial treatment according to SIOP-6 or SIOP-9 strategies. Med Pediatr Oncol 33:170, (abstract no. 11)

    Google Scholar 

  • Perlman EJ (2005) Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol 8:320–338

    Article  PubMed  Google Scholar 

  • Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH, Pritchard J (1991) Response rates in relapsed Wilms’ tumor. A need for new effective agents. Cancer 67:567–571

    Article  CAS  PubMed  Google Scholar 

  • Ramanathan RK, Rubin JT, Ohori NP, Belani CP (2000) Dramatic response of adult wilms tumor to paclitaxel and cisplatin. Med Pediatr Oncol 34:296–298

    Article  CAS  PubMed  Google Scholar 

  • Reinhard H, Schmidt A, Furtwangler R et al (2008) Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol Rep 20:463–467

    PubMed  Google Scholar 

  • Spreafico F, Bisogno G, Collini P et al (2008) Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer 51:23–28

    Article  PubMed  Google Scholar 

  • Spunt SL, Freeman BB 3rd, Billups CA et al (2007) Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol 25:2274–2280

    Article  PubMed  Google Scholar 

  • Tannous R, Giller R, Holmes E et al (2000) Intensive therapy for high risk (HR) relapsed Wilms’ tumor (WT). A CCG-4921/POG-9445 study report. In: Proceeding of ASCO, p 588a, (abstract no. 2315)

    Google Scholar 

  • Tournade MF, Lemerle J, Brunat-Mentigny M et al (1988) Ifosfamide is an active drug in Wilms’ tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol 6:793–796

    CAS  PubMed  Google Scholar 

  • Tubergen DG, Stewart CF, Pratt CB et al (1996) Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 18:352–361

    Article  CAS  PubMed  Google Scholar 

  • Turner CD, Gururangan S, Eastwood J et al (2002) Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol 4:102–108

    CAS  PubMed Central  PubMed  Google Scholar 

  • Vassal G, Giammarile F, Brooks M et al (2008) A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d’Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 44:2453–2460

    Article  CAS  PubMed  Google Scholar 

  • Venkatramani R, Malogolowkin MH, Mascarenhas L (2014) Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer 61:756–9

    Article  CAS  PubMed  Google Scholar 

  • Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J (2002) Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38:79–82

    Article  PubMed  Google Scholar 

  • Wagner LM, McAllister N, Goldsby RE et al (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48:132–139

    Article  PubMed  Google Scholar 

  • Witt O, Hammerling S, Stockklausner C et al (2009) 13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis. J Pediatr Hematol Oncol 31:296–299

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Pediatric Unit, Milano, Italy

    Filippo Spreafico

  2. Hematology-Oncology-Transplant Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Marcio H. Malogolowkin MD

Authors
  1. Filippo Spreafico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcio H. Malogolowkin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Filippo Spreafico .

Editor information

Editors and Affiliations

  1. Department of Developmental Biology and Cancer, Institute of Child Health, University College London, London, United Kingdom

    Kathy Pritchard-Jones

  2. Children's National Medical Center Center for Cancer & Blood Disorders, Washington, District of Columbia, USA

    Jeffrey S. Dome

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Spreafico, F., Malogolowkin, M.H. (2014). Treatment of Relapsed Wilms Tumor. In: Pritchard-Jones, K., Dome, J. (eds) Renal Tumors of Childhood. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44003-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44003-2_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44002-5

  • Online ISBN: 978-3-662-44003-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation